Prevention of atrial fibrillation in hypertensive patients;Prevención de la fibrilación auricular en el paciente hi pertenso

Medicina Clinica

Volumn 128, Issue 4, 2007, Pages 148-154

  Alonso, Vivencio Barrios ^a   Von Wichmann, Mariano De La Figuera ^b   Payeras, Antonio Coca ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CAP La Mina   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II receptor blockers; Atrial fibrillation; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN;

ARTERY EMBOLISM; DISEASE EXACERBATION; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INCIDENCE; PREVALENCE; PROPHYLAXIS; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 33847794423     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13098021     Document Type: Review

References (65)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al, and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee: on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003;289:2560-72.
2. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
3. González-Juanatey JR, Mazón P, Soria F, Barrios V, Rodríguez-Padial L, Bertomeu V. Actualización (2003) de las guías de práctica clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol. 2003;56:487-97.
4. Marín R, Armario P, Banegas JR, Campo C, De la Sierra A, Gorostidi M, et al. Guía española de hipertensión arterial 2005. Hipertension. 2005;22 Supl 2:1-83.
5. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-74.
6. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-22.
7. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41:218-23.
8. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476-84,
9. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
10. Page RL. Clinical practice. Newly diagnosed atrial fibrillation. N Engl J Med. 2004;351:2408-16.
11. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 2000;35:183-7.
12. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290:1049-56.
13. Scheinman MM. Atrial fibrillation and congestive heart failure. The intersection of two common diseases. Circulation. 1998;98:941-2.
14. Frost L, Engholm G, Johnsen S, Moller H, Henneberg EW, Husted S. Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation. Arch Intern Med. 2001;161:272-6.
15. González-Juanatey JR, Conthe P. Enfermedad cardiovascular y cardiopatía hipertensiva. Más allá del corazón. Med Clin (Barc). 2006;126:99-100.
16. Hennersdorf MG, Strauer BE. Arterial hypertension and cardiac arrhythmias. J Hypertens. 2001;19:167-77.
17. Wachtell K, Hornestam B, Letho M, Slotwiner DJ, Gerdts E, Olsen MH, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:705-11.
18. García-Acuña JM, González-Juanatey JR, Alegría E, González I, Listerri JL. La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol. 2002;55:943-52.
19. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns J, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences. J Am Coll Cardiol. 2001;38:1231-65.
20. Fuster V. Atrial fibrillation: an epidemiologic, scientific, and clinical challenge. Nature Clinical Practice. 2005;2:225.
21. Tsang TS, Miyasaka Y, Barnes M, Gersh BJ. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis. 2005;48:1-8.
22. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-61.
23. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370-5.
24. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham study. Am Heart J. 1996;131:790-5.
25. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects: the Cardiovascular Health Study. Am J Cardiol. 1994;74:236-41.
26. Tsang TS, Petty GW, Barnes ME, O'Fallon WM, Bailey KR, Wiebers DO, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol. 2003;42:93-100.
27. Masiá R, Sala J, Marrugat J, Pena A y los investigadores del estudio REGICOR. Prevalencia de fibrilación auricular en la provincia de Girona: el estudio REGICOR. Rev Esp Cardiol. 2001;54:1240.
28. Planas F, Antúnez F, Poblet T, Pujol M, Romero C, Sadurní J, et al. Perfil clínico de la fibrilación auricular paroxística idiopática (registro FAP). Rev Esp Cardiol. 2001;54:838-44.
29. González-Juanatey JR, Alegría E, Lozano JV, Llisterri JL, García-Acuña JM, González-Maqueda I. Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol. 2001;54:139-49.
30. García-Acuña JM, González-Juanatey JR, Alegría E, González-Maqueda I, Llisterri JL. La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol. 2002;55:943-52.
31. Tsang TS, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc. 2001;76:467-75.
32. Wilhelmsen L, Rosengren A, Lapas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med. 2001;250:382-9.
33. Yan Y, Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Comorbidity indices to predict mortality from Medicare data: results from the national registry of atrial fibrillation. Med Care. 2005;43:1073-7.
34. Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004;292:2471-7.
35. Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah AS, Habib RH. Obesity and the risk of new-onset atrial fibrillation after cardiac surgery. Circulation. 2005;112:3247-55.
36. Dernellis J, Panaretou M. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am J Cardiol. 2006;97:245-8.
37. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
38. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000;35:1669-77.
39. Goette A, Arndt M, Rocken C, Spiess A, Staack T, Geller JC, et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation. 2000;101:2678-81.
40. Dostal DE. Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. Hypertension. 2001;37:841-4.
41. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608-14.
42. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res. 2003;60:315-25.
43. González-Juanatey JR, Grigorian L. Tratamiento de la hipertensión arterial en pacientes con fibrilación auricular. Implicaciones para la práctica clínica. En: Manejo de la fibrilación auricular en el paciente hipertenso. Madrid: Sociedad Española de Cardiología 2006. p. 51-58.
44. L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004;44:159-64.
45. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Nicklason A, et al. Effect of angiotensin converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet. 1999;353:611-6.
46. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet. 1999;354:1751-6.
47. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-9.
48. Fogari R, Mugellini A, Destro M, Corradi L, Zoppi A, Fogari E, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol. 2006;47:46-50.
49. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376-80.
50. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107:2926-31.
51. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548-57.
52. Van den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KI. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1995;1:355-63.
53. Murray KT, Rottman JN, Arbogast PG, Shemanski L, Primm RK, Campbell WB, et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004;1:669-75.
54. Madrid AH, Bueno MG, Rebollo JM, Marín I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation. 2002;106:331-6.
55. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24:2090-8.
56. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006;27:512-8.
57. Kalus J, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol. 2006;46:21-8.
58. Devereux RB, Palmieri V, Liu JE, Watchtell K, Bella JN, Boman K, et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens. 2002;20:1445-50.
59. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart. 2001;86:527-32.
60. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan Heart Failure: Asssessment of Reduction in Mortality and Morbidity (CHARM) program. Am Heart J. 2006;151:992-8.
61. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and antengiosin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832-9.
62. Julius J, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine. Lancet. 2004;363:2022-31.
63. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21:875-86.
64. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719-28.
65. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al. Rationale, design, and baseline characteristics of 2 large, simple randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J. 2004;148:52-61.